<H1>Chapter DOI: 10.1208/aapsj070116<br/>Cited-By Count: 6</H1><table border="1" width="30%"><tr><td>Total References</td><td>24</td></tr><tr><td>Springer references</td><td>2</td></tr><tr><td>Non Springer references</td><td>22</td></tr><tr><td>BibStructured Count</td><td width="10%">24</td></tr><tr><td>BibUnstructured Count</td><td width="10%">0</td></tr><tr><td>DOI already available in SpringerLink</td><td>19</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>1</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>1</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>2</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>2</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>1</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibArticle</td><td>Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.<Emphasis Type="Italic">Eur J Cancer.</Emphasis> 2001;37:1590&#8211;1598.</td><td><a href=http://dx.doi.org/10.1016/S0959-8049(01)00171-X>10.1016/S0959-8049(01)00171-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2</td><td>BibArticle</td><td>Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization.<Emphasis Type="Italic">J Pharm Sci.</Emphasis> 1996;85:1017&#8211;1025.</td><td><a href=http://dx.doi.org/10.1021/js950534b>10.1021/js950534b</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3</td><td>BibArticle</td><td>Jacobsen J, Bjerregaard S, Pedersen M. Cyclodextrin inclusion complexes of antimycotics intended to act in the oral cavity-drug supersaturation, toxicity on TR146 cells and release from a delivery system.<Emphasis Type="Italic">Eur J Pharm Biopharm.</Emphasis> 1999;48:217&#8211;224.</td><td><a href=http://dx.doi.org/10.1016/S0939-6411(99)00043-0>10.1016/S0939-6411(99)00043-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4</td><td>BibArticle</td><td>Mura P, Liguori A, Bramanti G, Bettinetti GP, Campisi E, Faggi E. Improvement of dissolution properties and microbiological activity of miconazole and econazole by cyclodextrin complexation.<Emphasis Type="Italic">Eur J Pharm Biopharm.</Emphasis> 1992;38:119&#8211;123.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR5</td><td>BibArticle</td><td>Pedersen M. Isolation and antimycotic effect of a genuine miconazole &#946;-cyclodextrin complex.<Emphasis Type="Italic">Eur J Pharm Biopharm.</Emphasis> 1994;40:19&#8211;23.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR6</td><td>BibArticle</td><td>Piel G, Evrard B, Fillet M, Llabres G, Delattre L. Development of a non-surfactant parenteral formulation of miconazole by the use of cyclodextrins.<Emphasis Type="Italic">Int J Pharm.</Emphasis> 1998;169:15&#8211;22.</td><td><a href=http://dx.doi.org/10.1016/S0378-5173(98)00103-3>10.1016/S0378-5173(98)00103-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7</td><td>BibArticle</td><td>Rajewski RA, Stella VJ. Pharmaceutical applications of cyclodextrins. II. In vivo drug delivery.<Emphasis Type="Italic">J Pharm Sci.</Emphasis> 1996;85:1142&#8211;1165.</td><td><a href=http://dx.doi.org/10.1021/js960075u>10.1021/js960075u</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8</td><td>BibArticle</td><td>Tenjarla S, Puranajoti P, Kasina R, Mandal T. Preparation, characterization, and evaluation of miconazole-cyclodextrin complexes for improved oral and topical delivery.<Emphasis Type="Italic">J Pharm Sci.</Emphasis> 1998;87:425&#8211;429.</td><td><a href=http://dx.doi.org/10.1021/js970361l>10.1021/js970361l</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9</td><td>BibArticle</td><td>Hostetler JS, Hanson LH, Stevens DA. Effect of cyclodextrin on the pharmacology of antifungal oral azoles.<Emphasis Type="Italic">Antimicrob Agents Chem.</Emphasis> 1992;36:477&#8211;480.</td><td><a href=http://dx.doi.org/10.1128/AAC.36.2.477>10.1128/AAC.36.2.477</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, FirstPage, Author_FamilyName_1, Year, VolumeID, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR10</td><td>BibArticle</td><td>Van Hees T, Piel G, Evrard B, Otte X, Thunus L, Delattre L. Application of supercritical fluid carbon dioxide for the preparation of a piroxicam-&#946;-cyclodextrin inclusion compound.<Emphasis Type="Italic">Pharm Res.</Emphasis> 1999;16:1864&#8211;1870.</td><td><a href=http://dx.doi.org/10.1023/A:1018955410414>10.1023/A:1018955410414</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11</td><td>BibArticle</td><td>Charoenchaitrakool M, Dehghani F, Foster NR. Utilization of supercritical carbon dioxide for complex formation of ibuprofen and methyl-&#946;-cyclodextrin.<Emphasis Type="Italic">Int J Pharm.</Emphasis> 2002;239:103&#8211;112.</td><td><a href=http://dx.doi.org/10.1016/S0378-5173(02)00078-9>10.1016/S0378-5173(02)00078-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12</td><td>BibArticle</td><td>Lai S, Locci E, Piras A, Porcedda S, Lai A, Marongiu B. Imazalil-cyclomaltoheptaose (&#946;-cyclodextrin) inclusion complex: preparation by supercritical carbon dioxide and<Superscript>13</Superscript>C CPMAS and<Superscript>1</Superscript>H NMR characterization.<Emphasis Type="Italic">Carbohydr Res.</Emphasis> 2003;338:2227&#8211;2232.</td><td><a href=http://dx.doi.org/10.1016/S0008-6215(03)00358-6>10.1016/S0008-6215(03)00358-6</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13</td><td>BibArticle</td><td>Barillaro V, Bertholet P, Henry de Hassonville S, et al. Effect of acidic ternary compounds on the formation of miconazole/cyclodextrin inclusion complexes by means of supercritical carbon dioxide.<Emphasis Type="Italic">J Pharm Pharm Sci.</Emphasis> 2004;7:378&#8211;388.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR14</td><td>BibArticle</td><td>Kararli TT. Comparison of the gatrointestinal anatomy, physiology and biochemistry of humans and commonly used laboratory animals.<Emphasis Type="Italic">Biopharm Drug Dispos.</Emphasis> 1995;16:351&#8211;380.</td><td><a href=http://dx.doi.org/10.1002/bdd.2510160502>10.1002/bdd.2510160502</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15</td><td>BibArticle</td><td>Davis SS, Illum L, Hinchcliffe M. Gastrointestinal transit of dosage forms in the pig.<Emphasis Type="Italic">J Pharm Pharmacol.</Emphasis> 2001;53:33&#8211;39.</td><td><a href=http://dx.doi.org/10.1211/0022357011775163>10.1211/0022357011775163</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16</td><td>BibArticle</td><td>Larsen F, Jensen BH, Olesen HP, Larsen P. Multiple oral administration of a ketoprofen-dextran ester prodrug in pigs: assessment of gastrointestinal bioavailability by deconvolution.<Emphasis Type="Italic">Pharm Res.</Emphasis> 1992;9:915&#8211;919.</td><td><a href=http://dx.doi.org/10.1023/A:1015805000595>10.1023/A:1015805000595</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR17</td><td>BibArticle</td><td>Hildebrand H, McDonald FM, Windt-Hanke E. Characterization of oral sustained release preparations of iloprost in the pig model by plasma level monitoring.<Emphasis Type="Italic">Prostaglandins.</Emphasis> 1991;41:473&#8211;486.</td><td><a href=http://dx.doi.org/10.1016/0090-6980(91)90053-I>10.1016/0090-6980(91)90053-I</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18</td><td>BibArticle</td><td>Piel G, Evrard B, Van Hees T, Delattre L. Comparison of the IV pharmacokinetics in sheep of miconazole-cyclodextrin solutions and a micellar solution.<Emphasis Type="Italic">Int J Pharm.</Emphasis> 1999;180:41&#8211;45.</td><td><a href=http://dx.doi.org/10.1016/S0378-5173(98)00403-7>10.1016/S0378-5173(98)00403-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19</td><td>BibBook</td><td>US Food and Drug Administration Center for Drug Evaluation and Research.<Emphasis Type="Italic">Bioanalytical Method Validation</Emphasis>. Rockville, Maryland: FDA Office of Training and Communication, Division of Communication Management, Drug Information Branch, 2001.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1002/0471463728.ch8>10.1002/0471463728.ch8</a></td><td><b>CrossRef-Web</b></td>
<td>BookTitle</td><td>CrossRef</td></tr><tr><td>CR20</td><td>BibArticle</td><td>Van Hees T, Piel G, Henry de Hassonville S, Evrard B, Delattre L. Determination of the free/included piroxicam ratio in cyclodextrin complexes: comparison between UV spectroscopy and differential scanning calorimetry.<Emphasis Type="Italic">Eur J Pharm Sci.</Emphasis> 2002;15:347&#8211;353.</td><td><a href=http://dx.doi.org/10.1016/S0928-0987(02)00018-0>10.1016/S0928-0987(02)00018-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR21</td><td>BibArticle</td><td>Stella VJ, Rao VM, Zannou EA, Zia V. Mechanisms of drug release from cyclodextrin complexes.<Emphasis Type="Italic">Adv Drug Deliv Rev.</Emphasis> 1999;36:3&#8211;16.</td><td><a href=http://dx.doi.org/10.1016/S0169-409X(98)00052-0>10.1016/S0169-409X(98)00052-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22</td><td>BibArticle</td><td>Uekama K, Hirayama F, Irie T. Cyclodextrin drug carrier systems.<Emphasis Type="Italic">Chem Rev.</Emphasis> 1998;98:2045&#8211;2076.</td><td><a href=http://dx.doi.org/10.1021/cr970025p>10.1021/cr970025p</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23</td><td>BibArticle</td><td>Savolainen J, Jarvinen K, Matilainen L, Jarvinen T. Improved dissolution and bioavailability of phenytoin by sulfobutylether-&#946;-cyclodextrin ((SBE) 7m-&#946;-CD) and hydroxypropyl-&#946;-cyclodextrin (HP-&#946;-CD) complexation.<Emphasis Type="Italic">Int J Pharm.</Emphasis> 1998;165:69&#8211;78.</td><td><a href=http://dx.doi.org/10.1016/S0378-5173(98)00004-0>10.1016/S0378-5173(98)00004-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24</td><td>BibArticle</td><td>Koester LS, Bertuol JB, Groch KR, et al. Bioavailability of carbamazepine: &#946;-cyclodextrin complex in beagle dogs from hydroxypropylmethylcellulose matrix tablets.<Emphasis Type="Italic">Eur J Pharm Sci.</Emphasis> 2004;22:201&#8211;207.</td><td><a href=http://dx.doi.org/10.1016/j.ejps.2004.03.010>10.1016/j.ejps.2004.03.010</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>